Teva Pharma (TEVA) Says it Remains Confident in Patient and Physician Loyalty to COPAXONE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Teva Pharma (TEVA) PT Lowered to $15 at Morgan Stanley
October 5, 2017 8:58 AM EDTMorgan Stanley lowered its price target on Teva Pharma (NYSE: TEVA) to $15.00 (from $16.00) while maintaining a Underweight rating.
... MoreTeva Pharma (TEVA) PT Lowered to $21 at Barclays; Generic Copaxone 40mg Approval 'Will Offset Some Contracting Strategies... Hurt Sentiment'
October 4, 2017 12:17 PM EDTBarclays lowered its price target on Teva Pharma (NYSE: TEVA) to $21.00 (from $23.00) while maintaining a Equalweight rating, following an update on the U.S. Specialty Pharmaceutical industry, as the FDA recently approved a generic Copaxone formulation.
Analyst Douglas Tsao notes a... More
Mylan (MYL) PT Raised to $36 at Cowen; Reiterates Market Perform
October 4, 2017 10:44 AM EDTCowen raised its price target on Mylan (NASDAQ: MYL) to $36.00 (from $30.00) while maintaining a Market Perform rating. Cowen updated its model to reflect a potential $800MM in generic Copaxone contribution in 2018, and then modestly declining with other competition.
With this approval the... More
